<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: AIMS/OBJECTIVE: Conflicting data regarding cardiovascular effects of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) and extra-skeletal effects of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> supported the need for a definitive trial </plain></SENT>
<SENT sid="1" pm="."><plain>The Thiazolidinedione Intervention with <z:chebi fb="27" ids="27300">vitamin D</z:chebi> Evaluation (TIDE) trial aimed to assess the effects of TZDs (<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>) on cardiovascular outcomes and the effects of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> (cholecalciferol) on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A large multicentre 3 × 2 factorial double-blind placebo-controlled randomised trial recruited from outpatient primary care and specialty clinics in 33 countries </plain></SENT>
<SENT sid="3" pm="."><plain>From June 2009 to July 2010, 1,332 people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and other <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> aged ≥ 50 years whose HbA(1c) was 6.5-9.5% (48-80 mmol/mol) when using two or fewer <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drugs were randomised by a central computer system to placebo (n = 541), <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> 4-8 mg/day (n = 399) or <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30-45 mg/day (n = 392); 1,221 participants were randomised to placebo (n = 614) or <z:chebi fb="27" ids="27300">vitamin D</z:chebi> 1,000 IU/day (n = 607) </plain></SENT>
<SENT sid="4" pm="."><plain>Participants and <z:hpo ids='HP_0000001'>all</z:hpo> study personnel were blind to treatment allocation </plain></SENT>
<SENT sid="5" pm="."><plain>The primary outcome for the TZD arm was the composite of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo> or cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, and for the <z:chebi fb="27" ids="27300">vitamin D</z:chebi> arm it was <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> randomised participants were included in the primary analysis </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: From the study design, 16,000 people were to be followed for approximately 5.5 years </plain></SENT>
<SENT sid="8" pm="."><plain>However, the trial was stopped prematurely because of regulatory concerns after a mean of 162 days without consideration of the accrued data </plain></SENT>
<SENT sid="9" pm="."><plain>In the TZD arm, the cardiovascular outcome occurred in five participants (0.9%) in the placebo groups and three participants (0.4%) in the TZD groups (two allocated to <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, one to <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>) </plain></SENT>
<SENT sid="10" pm="."><plain>In the <z:chebi fb="27" ids="27300">vitamin D</z:chebi> arm, the primary outcome occurred in three participants (0.5%) in the placebo group and in two participants (0.3%) receiving <z:chebi fb="27" ids="27300">vitamin D</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Adverse events were comparable in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: Uncertainty persists regarding the clinically relevant risks and benefits of TZDs and <z:chebi fb="27" ids="27300">vitamin D</z:chebi> because of the early cancellation of this comprehensive trial </plain></SENT>
</text></document>